Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Appendix
Available only for authorised users
Literature
1.
Elder ME. SCID due to Zap-70 deficiency. J Pediatr Hematol Oncol. 1997;19(6):546–50.CrossRef
2.
Walkovich K, Vander Lugt M. ZAP70-Related Combined Immunodeficiency. 2009 Oct 20 [Updated 2017 Jun 8]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. https://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK20221/​. Accessed 10 April 2019.
3.
Cauwe B, Tian L, Franckaert D, Pierson W, Staats KA, Schlenner SM, et al. A novel ZAP70 mutation with reduced protein stability demonstrates the rate-limiting threshold for ZAP70 in T cell receptor signaling. Immunology. 2014;141:377–87.CrossRef
4.
Grazioli S, Bennett M, Hildebrand KJ, Vallance H, Turvey SE, Junker AK. Limitation of TREC based newborn screening for ZAP70 severe combined immunodeficiency. Clin Immunol. 2014;153:209–10.CrossRef
5.
Roifman CM, et al. Characterization of zeta-associated protein, 70 Kd (ZAP70)-deficient human lymphocytes. JACI. 2010;126:1126–233.
Metadata
Title
Novel Compound Heterozygous Mutations in ZAP70 Leading to a SCID Phenotype with Normal Downstream In vitro Signaling
Authors
Kelsey Kaman
Monique Abrams
Kerry Dobbs
Luigi D. Notarangelo
Ottavia M. Delmonte
Boaz Palterer
Sung-Yun Pai
Alicia Johnston
Publication date
01-02-2021
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 2/2021
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-020-00913-4

Other articles of this Issue 2/2021

Journal of Clinical Immunology 2/2021 Go to the issue

Original Article

N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects

Correction

Correction to: Infections in Infants with SCID: Isolation, Infection Screening and Prophylaxis in PIDTC Centers

Original Article

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis

Commentary

In Memoriam: Asghar Aghamohammadi (May 30, 1951–November 14, 2020)

Original Article

Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes

Letter to Editor

Infection Due to Serratia sp. in Chronic Granulomatous Disease—Is the Incidence Low in Tropical Countries?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits